|
COPYRIGHT 2004 NewsRX
2004 JUL 24 - (NewsRx.com & NewsRx.net) -- Bristol-Myers Squibb Company (BMY) and Otsuka Pharmaceutical Co., Ltd., announced the European launch of Abilify (aripiprazole), the first in a new generation of antipsychotic medications, at the 24th Annual Meeting of the Collegium Internationale Neuro-Psychopharmacologicum (CINP), a key psychiatry conference held in Paris, France.
Two in every three patients rated Abilify as "much better, I prefer this medication" 8 weeks after switching from a previous antipsychotic treatment, according to results of BETA (Broad Effectiveness Trial with Aripiprazole), a naturalistic study involving 1500 patients, presented at the congress.
"Abilify offers an effective new option for millions of people affected by schizophrenia in Europe," said professor Rajiv Tandon, professor of...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
